Xhance (formerly OPN-375) is a drug-device product for the treatment of nasal polyposis in adults. The product combines a novel, closed palate, bidirectional drug delivery platform with fluticasone propionate, which is a topical steroid. The drug delivery device is powered by the user’s own breath. It has both a mouthpiece and a sealing nosepiece designed to expand the upper part of the nasal valve. The user exhales into the mouthpiece, closing their soft palate and isolating the nasal cavity from their mouth and lungs. The exhaled breath propels the medication through the nosepiece and beyond the nasal valve deep into the sinuses.


If you have a Hayes login, click here to view the full report on the Knowledge Center.